9,10-dimethyl-1,2-benzanthracene has been researched along with daphnetin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jha, S; Kumar, A; Pattanayak, SP | 1 |
| Jha, S; Kumar, A; Pattanayak, SP; Sunita, P | 1 |
2 other study(ies) available for 9,10-dimethyl-1,2-benzanthracene and daphnetin
| Article | Year |
|---|---|
Daphnetin ameliorates 7,12-dimethylbenz[a]anthracene-induced mammary carcinogenesis through Nrf-2-Keap1 and NF-κB pathways.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Antioxidants; Biomarkers, Tumor; Carcinogenesis; Cytokines; Female; Fluorescent Antibody Technique; Gene Expression Regulation, Neoplastic; Kelch-Like ECH-Associated Protein 1; Lipid Peroxidation; Mammary Neoplasms, Experimental; Neoplasm Proteins; NF-E2-Related Factor 2; NF-kappa B; Rats, Sprague-Dawley; RNA, Messenger; Signal Transduction; Umbelliferones | 2016 |
7,8-Dihydroxycoumarin exerts antitumor potential on DMBA-induced mammary carcinogenesis by inhibiting ERα, PR, EGFR, and IGF1R: involvement of MAPK1/2-JNK1/2-Akt pathway.
Topics: 17-Hydroxysteroid Dehydrogenases; 9,10-Dimethyl-1,2-benzanthracene; Animals; Antineoplastic Agents; Aromatase; Biomarkers, Tumor; Carcinogens; Cell Proliferation; Cytokines; Dose-Response Relationship, Drug; ErbB Receptors; Estrogen Receptor alpha; Female; Humans; Inflammation Mediators; Ki-67 Antigen; Mammary Neoplasms, Experimental; MCF-7 Cells; Proliferating Cell Nuclear Antigen; Protein Kinases; Rats, Sprague-Dawley; Receptor, IGF Type 1; Receptors, Progesterone; Umbelliferones | 2018 |